GH vs IQV vs TEM Stock Comparison

Guardant Health, Iqvia Holdings and Tempus AI Prices as of Nov 13, 2026 Peers: Industry group
GH Guardant Health, Inc.
$151.70 -6.9% 1M +61.2% 1Y
Market cap
$19.41B
P/E
–
Revenue (TTM)
$1.28B
Div. yield
–
Diagnostic Labs Healthcare
3 wins
IQV Iqvia Holdings Inc.
$264.96 +1.1% 1M +18.5% 1Y
Market cap
$43.18B
P/E
31.0x
Revenue (TTM)
$17.31B
Div. yield
–
Contract Research Healthcare
5 wins
TEM Tempus AI, Inc.
$71.60 +4.8% 1M +5.4% 1Y
Market cap
$12.08B
P/E
–
Revenue (TTM)
$1.51B
Div. yield
–
Diagnostic Labs Healthcare

Head to Head

8 decided of 12

Iqvia Holdings leads on 5 of the 12 questions below (Iqvia Holdings 5, Guardant Health 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGHIQVTEMLeader
Larger companyMarket capitalisation $19.41B $43.18B $12.08B IQV
Cheaper on earningsLower P/E, profitable companies only -40.0x 31.0x -63.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 21.8x — –
Faster revenue growthRevenue growth, trailing twelve months +41.7% +8.8% +36.6% GH
More profitableNet margin, trailing twelve months -37.9% 8.1% -12.5% IQV
Better return on capitalReturn on invested capital — 8.2% -57.2% IQV
Less leveragedLower net debt / EBITDA — 3.9x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +61.2% +18.5% +5.4% GH
Better 5-year returnAnnualised price return, 5 years +7.9%/yr +0.8%/yr — GH
Less volatileAnnualised volatility, 1 year 53.0% 40.8% 77.8% IQV
Higher overall scoreMean of the five percentile scores vs peers 27/100 71/100 37/100 IQV

Percentile Scorecard

GHIQVTEM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGHIQVTEM
Valuation 15 #84 of 99 80 #3 of 11 11 #88 of 99
Growth 44 #50 of 89 60 #5 of 11 61 #35 of 89
Profitability 9 #84 of 92 90 #2 of 11 19 #75 of 92
Financial Health 54 #48 of 103 25 #10 of 13 56 #46 of 103
Shareholder Returns 13 #55 of 63 100 #1 of 8 –
Overall 27 71 37
  • GH ranked among 103 companies in Healthcare Providers
  • IQV ranked among 13 companies in Pharma Services
  • TEM ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGHIQVTEMSPY
1 month -6.9%+1.1%+4.8% -2.0%
3 months -3.5%+11.9%+37.4% -2.8%
6 months +59.8%+56.7%+63.0% +2.0%
Year to date +48.5%+17.5%+21.3% +10.6%
1 year +61.2%+18.5%+5.4% +12.2%
3 years +519.4%+32.2%— +68.1%
3 years, per year +83.7%+9.7%— +18.9%
5 years +46.1%+4.0%— +61.4%
5 years, per year +7.9%+0.8%— +10.1%
10 years —+243.5%— +248.5%
10 years, per year —+13.1%— +13.3%

Risk

MeasureGHIQVTEMSPY
Volatility, 1Y 53.0%40.8%77.8% 13.6%
Downside volatility, 1Y 50.7%39.9%66.1% 13.9%
Beta vs S&P 500, 1Y 1.320.712.41 1.00
Return / volatility, 1Y 1.150.450.07 0.90
Max drawdown, 5Y -85.0%-51.5%-59.8% -25.4%
From 52-week high -19.0%-5.2%-15.8% -3.2%
52-week high $187.22$279.38$85.08 $779.14
52-week low $78.60$156.66$41.55 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGHIQVTEM
P/E now vs peer median -42.0xmedian 22.4x 31.3xmedian 34.7x -68.6xmedian 22.4x
P/S now vs peer median 16.0xmedian 1.3x 2.5xmedian 2.5x 8.4xmedian 1.3x
EV/EBITDA now vs peer median -40.6xmedian 14.2x 16.6xmedian 29.1x -131.1xmedian 14.2x
P/FCF now vs peer median -88.0xmedian 19.0x 21.0xmedian 21.0x -92.7xmedian 19.0x
P/B now vs peer median -74.1xmedian 2.6x 6.4xmedian 1.6x 25.4xmedian 2.6x
PEG now vs peer median -72.47median 0.84 2.71median 1.98 —median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGHIQVTEM
Revenue $1.28B $17.31B $1.51B
Gross profit $833.70M $5.72B $972.95M
Operating income -$504.04M $2.22B -$278.90M
Net income -$485.07M $1.40B -$189.29M
Free cash flow -$232.15M $2.08B -$136.79M
R&D $386.67M – $197.35M
EPS (diluted) $-3.61 $8.35 $-1.04
Cash & equivalents $1.03B $2.25B $590.48M
Total debt – $16.07B –
Shares (diluted) 134.42M 167.00M 181.31M
Enterprise value $15.02B $34.43B $9.23B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGHIQVTEM
P/E -42.0x 31.3x -68.6x
P/FCF -88.0x 21.0x -92.7x
P/Operating cash flow -117.8x 16.0x -117.1x
P/S 16.0x 2.5x 8.4x
P/B -74.1x 6.4x 25.4x
P/Tangible book -67.9x 21.3x 61.4x
EV/EBITDA -40.6x 16.6x -131.1x
EV/EBIT -38.5x 25.8x -43.2x
EV/Revenue 15.2x 3.3x 8.0x
EV/FCF -83.6x 27.6x -88.1x
EV/Operating cash flow -111.9x 20.9x -111.2x
PEG (3Y EPS CAGR) -72.47 2.71 –

Growth

14 metrics
MetricGHIQVTEM
Revenue growth (1Y) 41.7% 8.8% 36.6%
Revenue CAGR (3Y) 33.6% 5.2% –
Gross profit growth (1Y) 44.9% 6.6% 42.6%
Gross profit CAGR (3Y) – 3.4% –
Operating income growth (1Y) -13.9% 1.7% -15.2%
Operating income CAGR (3Y) 0.6% 6.2% –
Net income growth (1Y) -21.6% 9.0% 7.2%
Net income CAGR (3Y) -3.9% 7.8% –
EPS growth (1Y) -12.9% 11.7% 10.4%
EPS CAGR (3Y) 0.6% 11.5% –
Operating cash flow growth (1Y) 22.2% -2.4% 50.9%
Operating cash flow CAGR (3Y) 19.9% 11.7% –
Free cash flow growth (1Y) 11.5% -6.0% 44.1%
Free cash flow CAGR (3Y) 13.9% 16.3% –

Profitability

14 metrics
MetricGHIQVTEM
Gross margin 65.2% 33.1% 64.5%
EBITDA margin -37.4% 20.0% -6.1%
Operating margin -39.4% 12.8% -18.5%
Pretax margin -38.0% 9.0% -12.2%
Net margin -37.9% 8.1% -12.5%
FCF margin -18.2% 12.0% -9.1%
Operating cash flow margin -13.6% 15.8% -7.2%
Return on equity – 21.4% -40.4%
Return on assets -25.5% 4.6% -7.9%
Return on invested capital – 8.2% -57.2%
Return on capital employed -33.0% 9.9% -14.1%
Asset turnover 0.7x 0.6x 0.6x
Cash conversion (OCF / net income) 0.4x 2.0x 0.6x
Stock comp / revenue 16.5% 1.8% 13.3%

Financial Health

11 metrics
MetricGHIQVTEM
Debt / assets – 52.7% –
Debt / equity – 2.4x –
Net debt / EBITDA – 3.9x –
Debt / FCF – 7.7x –
Liabilities / assets 114.6% 77.7% 79.6%
Equity / assets -14.6% 22.3% 20.4%
Interest coverage -96.6x 2.8x -6.0x
Current ratio 3.6x 0.8x 2.6x
Quick ratio 3.3x 1.0x 2.4x
Cash ratio 2.8x 0.3x 1.5x
Altman Z-score 3.60 2.24 3.04

Shareholder Returns

7 metrics
MetricGHIQVTEM
Dividend yield – – –
Net buyback yield -2.0% 2.8% –
Shareholder yield -2.0% 2.8% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGHIQVTEM
Forward P/E – 21.8xFY2026 –
EPS, next fiscal year $-3.46FY2026 $12.16FY2026 $-0.05FY2026
EPS growth, next FY – +2.0%FY2026 –
EPS growth, the year after – +11.4% –
Revenue, next fiscal year $1.43BFY2026 $18.65BFY2026 $1.64BFY2026
Revenue growth, next FY +45.5%FY2026 +14.4%FY2026 +29.0%FY2026
Revenue growth, the year after +26.0% -3.3% +25.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGHIQVTEM
Held by institutions 100.0% 94.1% 63.0%
Institutions holding 597 1,085 486
Change in shares held, QoQ -2.5% +0.3% +5.0%
Institutions buying 356 532 285
Institutions selling 180 424 119
Buyers to sellers 1.98 1.25 2.39

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GHIQVTEM
GH 1.00 0.31 0.54
IQV 0.31 1.00 0.39
TEM 0.54 0.39 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GH, IQV and TEM?

Iqvia Holdings (IQV) is the largest by market capitalisation: Guardant Health (GH) $19.41B, Iqvia Holdings (IQV) $43.18B, Tempus AI (TEM) $12.08B.

Which company is growing faster?

Guardant Health (GH) grew revenue fastest over the trailing twelve months: Guardant Health (GH) +41.7%, Iqvia Holdings (IQV) +8.8%, Tempus AI (TEM) +36.6%.

Which company is more profitable?

Iqvia Holdings (IQV) has the highest net margin (Guardant Health (GH) -37.9%, Iqvia Holdings (IQV) 8.1%, Tempus AI (TEM) -12.5%). On return on invested capital, Iqvia Holdings (IQV) leads (Iqvia Holdings (IQV) 8.2%, Tempus AI (TEM) -57.2%).

Which stock has performed better?

Over the past year Guardant Health (GH) returned the most: Guardant Health (GH) +61.2%, Iqvia Holdings (IQV) +18.5%, Tempus AI (TEM) +5.4%. Over five years, Guardant Health (GH) compounded fastest (Guardant Health (GH) +7.9%/yr, Iqvia Holdings (IQV) +0.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Iqvia Holdings (IQV) has been the steadiest (Guardant Health (GH) 53.0%, Iqvia Holdings (IQV) 40.8%, Tempus AI (TEM) 77.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GH, IQV and TEM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Iqvia Holdings (IQV) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.